VIYASH259.00

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹11,314 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+13.3+120.5
EBITDA Growth+163.4+303.3
EBIT Growth+75,766.7+339.4
Net Income Growth+208.9+596.4
EPS Growth+161.1+364.8
Total Assets Growth+4.0+188.9
Total Equity Growth+8.1+304.3
Cash from Operations Growth+172.5+287.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.